SAB Biotherapeutics (SABS) announced that the Company will give several oral presentations at the 2nd Asian Conference on Innovative Therapies for Diabetes Management being held December 9-11, 2025, in Singapore. Data to be presented will highlight the progress of SAB BIO’s lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for delaying the progression of T1D in new-onset, Stage 3 patients, including: Phase 1 study data showcasing the clinically validated, multi-specific mechanism of action of SAB-142. Phase 1 study data demonstrating immunomodulation without sustained lymphodepletion following dosing of SAB-142. Phase 1 study data demonstrating a favorable safety profile for SAB-142, characterized as not causing serum sickness or anti-drug antibodies at the target dose.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SABS:
- SAB Biotherapeutics Reports Positive Q3 2025 Earnings
- Sab Biotherapeutics, Inc. (SABS) Q3 Earnings Cheat Sheet
- Promising Clinical Developments and Strategic Decisions Justify Buy Rating for SAB Biotherapeutics
- Promising Phase 1 Data for SAB-142 Supports Buy Rating for SAB Biotherapeutics
- Sab Biotherapeutics’ New Study Targets Type 1 Diabetes Progression